Trial Profile
Phase II trial of a sequential regimen of induction chemotherapy with panitumumab and paclitaxel followed by radiotherapy plus panitumumab in patients with head and neck cancer, locally advanced non-candidates for treatment with platinum. (Ensayo de fase II de un régimen secuencial de quimioterapia de inducción con panitumumab y paclitaxel seguida de radioterapia más panitumumab en pacientes con cáncer de cabeza y cuello localmente avanzado que no son candidatos al tratamiento con derivados de platino)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Feb 2020
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Paclitaxel
- Indications Adenosquamous carcinoma; Carcinoma; Head and neck cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms PANTERA
- 17 Sep 2019 According to an Amgen media release, final results from this trial will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, Sept. 27-Oct. 1, 2019.
- 04 Feb 2013 Planned number of patients changed to 61.
- 04 Feb 2013 New trial record